What Pontifax does

Pontifax Venture Capital is a healthcare-dedicated venture capital firm founded in 2004 and headquartered in Herzliya, Israel. The firm manages approximately $1.2 billion in capital across roughly 100 portfolio companies developing transformative life sciences technologies across all development stages and therapeutic areas. It deploys capital into breakthrough biotech and medtech ventures, both by establishing its own companies and by partnering with existing management teams, with a stated hands-on approach to portfolio management.

The firm was co-founded by Eli Hurvitz (1932–2011), the former CEO and chairman of Teva Pharmaceuticals whose strategic stewardship built Teva into one of the world's largest pharmaceutical companies. His legacy continues to shape Pontifax's investment philosophy and network. The current leadership team comprises co-founder and CEO Tomer Kariv (Harvard Economics and Law), managing partner and co-founder Ran Nussbaum, and a small senior team including finance and scientific directors, all of whom take active board roles in portfolio companies. Ran Nussbaum's prior exits include Kite Pharma (sold to Gilead), cCAM Therapeutics (sold to Merck), ArQule (sold to Merck), and Emergence and Prevail (both sold to Lilly).

Pontifax's business model is that of a traditional healthcare-focused venture capital firm: it raises capital from limited partners, invests in privately held life sciences companies across stages, and generates returns through capital appreciation and exit events (trade sales, IPOs, and share buybacks). The firm operates a lean platform of fewer than 10 named professionals, supports portfolio companies with strategic planning and board governance, and participates in syndicates alongside other specialist investors such as Bpifrance, RA Capital, Pureos Bioventures, V-Bio Ventures, and Columbus Venture Partners. Recent realizations include participation in Keros Therapeutics' $375 million capital return program (approximately $181 million to Pontifax in October 2025).

Name

Pontifax

Legal name

Pontifax Venture Capital

Website

http://www.pontifax.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Pontifax Venture Capital is a healthcare-dedicated venture capital firm founded in 2004 in Herzliya, Israel, managing $1.2 billion across approximately 100 life sciences portfolio companies. It invests in breakthrough biotech and medtech ventures at all stages, partnering with or founding companies and taking active board roles.

Ownership category

akta.pro rank

Headquarters

HQ city

Herzliya

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Marketing channels1 record

Core offering

Pontifax is a healthcare-dedicated venture capital firm managing approximately $1.2 billion across about 100 portfolio companies developing breakthrough life sciences technologies. The firm invests in transformative pharmaceutical, biotech, and medtech companies at all development stages, taking a hands-on approach in portfolio management and deeply involved in charting the strategic course of each company. Pontifax both establishes its own companies and partners with existing management teams to nurture startups to maturity.

Product overview

Pontifax is a healthcare-dedicated venture capital firm, not a product company. It does not offer products or services in the traditional sense. Instead, it operates as an investment firm that manages a portfolio of approximately 100 life sciences companies, establishing its own companies and partnering with existing management to nurture startups to maturity. The firm invests in breakthrough, cutting-edge life sciences technologies at all development stages, with a focus on transformative solutions to substantial unmet needs. Pontifax does not have a product platform or individual product modules to describe.

Differentiator

Problem solved

Functional benefit

Products and services

• Pontifax Venture Capital Fund Healthcare-dedicated venture capital fund of approximately $1.2 billion that invests in transformative, cutting-edge life sciences technologies at all development stages. The fund supports about 100 portfolio companies developing breakthrough solutions to substantial unmet needs, and the firm both establishes its own companies and partners with existing management to nurture startups to maturity.
• Strategic Portfolio Management Services Hands-on portfolio management services for portfolio companies, including strategic planning support, board representation, and active involvement in charting the course of each company. Intended for life sciences startup founders and management teams requiring strategic guidance alongside capital.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves8 records

Expansion highlights5 records

Market position

Strengths1 record

Weaknesses4 records

Competitive moat4 records

Customer concentration

• LinkedInlinkedin.com/company/pontifax-venture-capital

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments119 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pontifax